Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | BRD2 | P25440 | 1/20 | 0.37 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.37 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17784762 | 0.84 | MAPT (0.45) | MAPTTHRBPTGDR2ALDH1A1KMT2A | |
| SCHEMBL19513362 | 0.83 | MAPT (0.53) | MAPTTHRBPTGDR2ALDH1A1KMT2A | |
| SCHEMBL17784859 | 0.83 | MAPT (0.47) | MAPTTHRBPTGDR2ALDH1A1KMT2A | |
| SCHEMBL19939512 | 0.82 | BRD4 (0.53) | MAPTPTGDR2ALDH1A1BRD4BRD2 | |
| SCHEMBL29242322 | 0.79 | MAPT (0.47) | MAPTTHRBPTGDR2ALDH1A1KMT2A | |
| SCHEMBL19513477 | 0.79 | MAPT (0.41) | MAPTTHRBPTGDR2ALDH1A1KMT2A | |
| SCHEMBL19501371 | 0.79 | MAPT (0.50) | MAPTTHRBPTGDR2ALDH1A1KMT2A | |
| SCHEMBL24863522 | 0.76 | MAPT (0.43) | MAPTTHRBPTGDR2ALDH1A1KMT2A | |
| SCHEMBL28894823 | 0.76 | MAPT (0.43) | MAPTTHRBPTGDR2KMT2ABRD4 | |
| SCHEMBL8276897 | 0.76 | MEN1 (0.50) | MAPTTHRBPTGDR2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203012-A1 | SOLID FORMS OF A PLASMA KALLIKREIN INHIBITOR AND SALTS THEREOF | CROWE DAVID MALCOLM (GB) | 2023-06-29 | — | — | US | disclosed |
| US-20230203012-A1 | SOLID FORMS OF A PLASMA KALLIKREIN INHIBITOR AND SALTS THEREOF | CROWE DAVID MALCOLM (GB) | 2023-06-29 | — | — | US | disclosed |
| US-20230203012-A1 | SOLID FORMS OF A PLASMA KALLIKREIN INHIBITOR AND SALTS THEREOF | CROWE DAVID MALCOLM (GB) | 2023-06-29 | — | — | US | disclosed |
| US-11584735-B2 | Solid forms of a plasma kallikrein inhibitor and salts thereof | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-11584735-B2 | Solid forms of a plasma kallikrein inhibitor and salts thereof | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| WO-2023002219-A1 | TREATMENTS OF HEREDITARY ANGIOEDEMA | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023002219-A1 | TREATMENTS OF HEREDITARY ANGIOEDEMA | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-01-26 | — | — | WO | disclosed |
| WO-2022079446-A1 | TREATMENTS OF ANGIOEDEMA | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022079446-A1 | TREATMENTS OF ANGIOEDEMA | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-04-21 | — | — | WO | disclosed |
| US-20210171496-A1 | SOLID FORMS OF A PLASMA KALLIKREIN INHIBITOR AND SALTS THEREOF | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-06-10 | — | — | US | disclosed |
| US-20210171496-A1 | SOLID FORMS OF A PLASMA KALLIKREIN INHIBITOR AND SALTS THEREOF | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-06-10 | — | — | US | disclosed |
| EP-3717469-A1 | SOLID FORMS OF A PLASMA KALLIKREIN INHIBITOR AND SALTS THEREOF | Kalvista Pharmaceuticals Limited (GB) | 2020-10-07 | — | — | EP | disclosed |
| CN-111433197-A | Solid forms of plasma kallikrein inhibitors and salts thereof | 卡尔维斯塔制药有限公司 | 2020-07-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584735-B2 | Solid forms of a plasma kallikrein inhibitor and salts thereof | KLKB1, KLK1, KLK2 | MAPT 3230/4885THRB 4284/4885PTGDR2 3679/4885 |
| US-20210171496-A1 | SOLID FORMS OF A PLASMA KALLIKREIN INHIBITOR AND SALTS THEREOF | KLKB1, KLK1, KLK2 | MAPT 3230/4885THRB 4284/4885PTGDR2 3679/4885 |
| US-20230203012-A1 | SOLID FORMS OF A PLASMA KALLIKREIN INHIBITOR AND SALTS THEREOF | KLKB1, KLK1, KLK2 | MAPT 3260/4885THRB 4152/4885PTGDR2 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.